The leading cause of cancer death worldwide–where precision biomarkers could save the most lives.
Lung cancer kills more people than breast, prostate, and colorectal cancers combined. In 2020, 2.21 million new cases were diagnosed and 1.80 million deaths occurred. Every improvement in patient selection translates to thousands of lives saved.
Current PD-L1 testing uses arbitrary cutoffs (1%, 50%) that were established for regulatory approval, not biological optimization. The field recognizes this limitation but lacks better alternatives–until functional biomarkersLoading....
Leading Cause of Cancer Death: Lung cancer kills more people than breast, prostate, and colorectal cancers combined. NSCLC accounts for about 85% of cases.
Treatment Complexity: Treatment depends on stage, molecular markers (EGFR, ALK, KRAS, ROS1, etc.), and PD-L1 status. Multiple treatment options exist.
Four FDA-approved PD-L1 IHCLoading... assays exist for NSCLC, each with different antibodies, scoring systems, and cutoffs. Inter-assay concordance is imperfect, creating clinical confusion. More fundamentally, all measure expression–not function.
Patients with PD-L1 90% sometimes progress rapidly. This biological reality reflects the disconnect between protein presence and protein activity.
PD-L1 in Lung Cancer: PD-L1 expression helps guide checkpoint inhibitor use, but many "negative" patients respond and many "positive" patients don't.
The Gap: Better biomarkers could identify more responders and spare non-responders from ineffective treatment.
iFRETLoading...-based measurement of checkpoint engagement could address the fundamental limitation of expression-based testingLoading.... By quantifying whether PD-1 and PD-L1 are actually interacting at immune synapses within the tumor microenvironment, functional biomarkers report on the biology that checkpoint inhibitors target.
Given NSCLC's prevalence and mortality, even modest improvements in patient selection would have enormous clinical impact–potentially identifying thousands of additional responders annually while sparing non-responders from ineffective therapy and toxicity.
Validation Data: Lung cancer tissue was included in CTLA-4/CD80 validation studies (150-core TMA).
Potential Impact: If functional checkpoint measurement predicts response better than expression (as shown in melanoma), it could improve patient selection in the largest cancer killer.
Clinical Validation: NSCLC tissue was included in CTLA-4/CD80 antibody validation (150 cores TMA[4]). Given that PD-L1 expression guides ICI selection, functional engagement measurement could identify additional responders among PD-L1-low patients.
Click citation numbers to view full references in QF-Pro Applications & Clinical EvidenceLoading...
NSCLC validation: Lung cancer tissue validated CTLA-4/CD80 quantification (150 cores). Since PD-L1 expression guides therapy, functional measurement could expand responder identification.
